Eli Lilly and Co.

J&J completes sale of animal-drug business to Lilly

July 7, 2011
Associated Press
Janssen Pharmaceutica said Thursday it has completed the sale of its animal health business to Eli Lilly and Co. Inc.
More

Lilly loses bid to end revived Zyprexa U.K. patent case

July 5, 2011
Bloomberg News
The High Court in London on Tuesday denied Lilly’s request for a judgment without trial against Neopharma Ltd., the closely held company that has European marketing rights for the generic version of the drug known chemically as olanzapine.
More

Timing good for 2-in-1 biotech drugs

July 5, 2011
J.K. Wall
Eli Lilly and Co.’s foray into combination drugs is well-timed because the company could take advantage of some the world’s most successful biotech medicines, which are about to see their patents expire.
More

R&D spending soars above value of new drugs

July 5, 2011
J.K. Wall
To understand the depths of the pharmaceutical industry’s recent struggles, consider this: The industry has been spending $57 billion more per year on research and development than the value of the products it has been launching. That’s a problem.
More

Lilly asks judge to reject U.K. Zyprexa case

July 5, 2011
Bloomberg News
Eli Lilly and Co., the Indianapolis-based drugmaker whose best-selling schizophrenia medicine Zyprexa survived a patent challenge in Britain two years ago, has asked a United Kingdom judge to reject a parallel lawsuit by a generic drug company.
More

Lilly plans 10 drugs in final-stage trials by year's end

June 30, 2011
Bloomberg News
Lilly has 33 drugs in the second and third stages of clinical trials, including medicines for cancer, diabetes and Alzheimer’s disease, up from seven in 2005, the Indianapolis-based company said Thursday.
More

Lilly plans more investment in two-in-one drugs

June 28, 2011
J.K. Wall
Indianapolis-based drugmaker Eli Lilly on Tuesday will announce a multimillion-dollar investment to develop drugs that act like two medicines in one. Lilly plans to add more scientists to back the effort.
More

Zyprexa appeal rejected by Supreme Court

June 27, 2011
Bloomberg News
The U.S. Supreme Court has refused to revive a bid to press a $6.8 billion class-action suit against Eli Lilly and Co. over the marketing of Zyprexa, the company’s schizophrenia treatment.
More

Lilly, partner find no Bydureon effect on heart rhythm

June 27, 2011
Bloomberg News
Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said an analysis of a 148-patient trial found no evidence that their experimental Bydureon diabetes drug causes prolonged heart rhythms.
More

Lilly diabetes pill recommended for EU approval

June 24, 2011
Bloomberg News
Eli Lilly and Co. and Boehringer Ingelheim GmbH’s Trajenta medicine for Type 2 diabetes has been recommended for approval in Europe, putting the drug on track to enter the region’s market this year.
More

Lilly CEO: Immigration, tax laws slow innovation

June 23, 2011
Bloomberg News
The U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly & Co. CEO John Lechleiter plans to tell a technology conference Thursday.
More

EU approves Lilly's weekly diabetes drug Bydureon

June 21, 2011
Associated Press
European Union regulators have approved the first once-per-week diabetes medication, the companies that developed the drug said Tuesday.
More

Lilly enters collaboration deal with Swiss company

June 9, 2011
Associated Press
Drugmaker Eli Lilly and Co. has signed a deal with Swiss company Synthes Inc. to co-promote the bone drug Forteo and develop other potential orthopedic treatments.
More

Lilly wins ruling in dispute with Amylin over diabetes drugs

June 8, 2011
Bloomberg News
Eli Lilly and Co. won a ruling in a lawsuit brought by Amylin Pharmaceuticals Inc., which wants to prevent Lilly from using the same people to sell Amylin’s diabetes drug and that of a competitor.
More

Drug industry outlook negative through 2012, Moody’s says

June 8, 2011
Bloomberg News
Earnings growth will continue to slow in 2011 for most of the industry’s biggest companies, analyst predicts.
More

Roche wins as high court limits university patent rights

June 6, 2011
Bloomberg News
Monday's Supreme Court decision is a victory for companies that collaborate with universities in research. Indianapolis-based Eli Lilly and Co. was among the companies that supported Roche.
More

Lilly licenses Xigris rights to new biotech firm

May 23, 2011
J.K. Wall
Eli Lilly and Co. has agreed to license the U.S. marketing rights of its slow-selling sepsis drug Xigris to a newly created local biotech company called BioCritica that will seek to reinvigorate sales of the medication.
More

Growth in drug spending to slow as generics rise

May 18, 2011
Bloomberg News
The annual growth rate in spending on drugs may be cut in half over the next five years as people opt for less expensive generic medicines over brand-name treatments, a health-care research group said Wednesday, highlighting the challenge pharmaceutical firms like Eli Lilly and Co. are facing.
More

Amylin sues Lilly over drug development deal

May 16, 2011
Associated Press
Amylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim to develop and sell a competing product.
More

Eli Lilly's slumbering stock finally shows signs of lifeRestricted Content

May 14, 2011
Greg Andrews
Is it finally time to get some growth again out of a stock that since its debut on the public market 59 years ago has minted thousands of millionaires?
More

Lilly drug to detect Alzheimer’s criticized by consumer group

May 11, 2011
Bloomberg News
Eli Lilly and Co.’s Amyvid, an experimental imaging agent to detect signs of Alzheimer’s disease in the brain, shouldn’t be approved because of unreliable study results, a consumer-advocacy group said.
More

Two wins to bring Lilly modest sales

May 9, 2011
J.K. Wall
Finally, some new revenue. Eli Lilly and Co. will enjoy modest new sales later this year after U.S. regulators approved a new diabetes drug developed by a partner company, and another company nears approval on a drug that will produce royalties for the Indianapolis-based drugmaker.
More

Eli Lilly pledges $2.5 million to Mind Trust

May 5, 2011
J.K. Wall
Eli Lilly and Co. plans to give $2.5 million toward a new fundraising campaign by the Mind Trust, an Indianapolis-based education reform group.
More

FDA OKs new diabetes pill from Lilly, Boehringer

May 2, 2011
 IBJ Staff and Associated Press
The Food and Drug Administration says it has approved a new diabetes pill from Boehringer Ingelheim and Eli Lilly for patients who can't control their blood sugar with older medicines.
More

Lilly teams with Medtronic on Parkinson's treatment

April 26, 2011
J.K. Wall
Eli Lilly and Co. plans to use an implantable drug-delivery system made by Medtronic Inc. to precisely target patients' brains with an experimental drug for Parkinson’s disease.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT